Nimotuzumab Increases the Recovery Rate of Severe and Critical COVID-19 Patients: Evaluation in the Real-World Scenario

EGFR signaling is an important regulator of SARS-CoV induced lung damage, inflammation and fibrosis. Nimotuzumab is a humanized anti-EGFR antibody registered for several cancer indications. An expanded access study was conducted to evaluate the safety and recovery rate of severe and critical patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Diaz, Henrry, Jiménez, Jorge, Hernández, Aray, Valdés, Leivis, Martínez, Ariadna, Porto, Leonor, Hernández, Raity, Travieso, Nadina, Jova, Julio Héctor, Medel, Loipa, Troche, Mayelin, Gorte, Annia, Batista, Delmis, Valls, Ana Rosa, Cabrera, Leticia, Domeq, Milagros, Pérez, Leslie, Lorenzo-Luaces, Patricia, Sánchez, Lizet, Saavedra, Danay, Ramos, Mayra, Crombet, Tania
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353117/
https://www.ncbi.nlm.nih.gov/pubmed/35937253
http://dx.doi.org/10.3389/fpubh.2022.948520

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353117/
https://www.ncbi.nlm.nih.gov/pubmed/35937253
http://dx.doi.org/10.3389/fpubh.2022.948520

Ejemplares similares